Loading...
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
BACKGROUND: Trastuzumab emtansine (T-DM1) has been approved since 2013 for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who had received trastuzumab (Tmab) and taxane. However, no clinical trial has evaluated the efficacy of T-DM1 in those who...
Na minha lista:
| Udgivet i: | Breast Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Japan
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570684/ https://ncbi.nlm.nih.gov/pubmed/30737616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-019-00949-4 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|